|
1
|
Wahren-Herlenius M and Dörner T:
Immunopathogenic mechanisms of systemic autoimmune disease. Lancet.
382:819–831. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cook HT and Botto M: Mechanisms of
Disease: The complement system and the pathogenesis of systemic
lupus erythematosus. Nat Clin Pract Rheumatol. 2:330–337. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Avihingsanon Y and Hirankarn N: Major
lupus organ involvement: Severe lupus nephritis. Lupus.
19:1391–1398. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maroz N and Segal MS: Lupus nephritis and
end-stage kidney disease. Am J Med Sci. 346:319–323. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Borchers AT, Leibushor N, Naguwa SM,
Cheema GS, Shoenfeld Y and Gershwin ME: Lupus nephritis: A critical
review. Autoimmun Rev. 12:174–194. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang B and Farwell MA: microRNAs: A new
emerging class of players for disease diagnostics and gene therapy.
J Cell Mol Med. 12:3–21. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Taylor DD and Gercel-Taylor C: MicroRNA
signatures of tumor-derived exosomes as diagnostic biomarkers of
ovarian cancer. Gynecol Oncol. 110:13–21. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu LF and Liston A: MicroRNA in the immune
system, microRNA as an immune system. Immunology. 127:291–298.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rusek AM, Abba M, Eljaszewicz A, Moniuszko
M, Niklinski J and Allgayer H: MicroRNA modulators of epigenetic
regulation, the tumor microenvironment and the immune system in
lung cancer. Mol Cancer. 14:342015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang G, Tam LS, Li EK, Kwan BC, Chow KM,
Luk CC, Li PK and Szeto C: Serum and urinary free microRNA level in
patients with systemic lupus erythematosus. Lupus. 20:493–500.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hochberg MC: Updating the American College
of Rheumatology revised criteria for the classification of systemic
lupus erythematosus. Arthritis Rheum. 40:17251997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pitashny M, Schwartz N, Qing X, Hojaili B,
Aranow C, Mackay M and Putterman C: Urinary lipocalin-2 is
associated with renal disease activity in human lupus nephritis.
Arthritis Rheum. 56:1894–1903. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lorenzen JM, Haller H and Thum T:
MicroRNAs as mediators and therapeutic targets in chronic kidney
disease. Nat Rev Nephrol. 7:286–294. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dai Y, Sui W, Lan H, Yan Q, Huang H and
Huang Y: Comprehensive analysis of microRNA expression patterns in
renal biopsies of lupus nephritis patients. Rheumatol Int.
29:749–754. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ichii O, Otsuka-Kanazawa S, Horino T,
Kimura J, Nakamura T, Matsumoto M, Toi M and Kon Y: Decreased
miR-26a expression correlates with the progression of podocyte
injury in autoimmune glomerulonephritis. PLoS One. 9:e1103832014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Te JL, Dozmorov IM, Guthridge JM, Nguyen
KL, Cavett JW, Kelly JA, Bruner GR, Harley JB and Ojwang JO:
Identification of unique microRNA signature associated with lupus
nephritis. PLoS One. 5:e103442010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lu J, Kwan BC, Lai FM, Tam LS, Li EK, Chow
KM, Wang G, Li PK and Szeto CC: Glomerular and tubulointerstitial
miR-638, miR-198 and miR-146a expression in lupus nephritis.
Nephrology (Carlton). 17:346–351. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
de Assis LV and Isoldi MC: The function,
mechanisms, and role of the genes PTEN and TP53 and the effects of
asbestos in the development of malignant mesothelioma: A review
focused on the genes' molecular mechanisms. Tumour Biol.
35:889–901. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kitagishi Y and Matsuda S: Redox
regulation of tumor suppressor PTEN in cancer and aging (Review).
Int J Mol Med. 31:511–515. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li J, Yen C, Liaw D, Podsypanina K, Bose
S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al:
PTEN, a putative protein tyrosine phosphatase gene mutated in human
brain, breast, and prostate cancer. Science. 275:1943–1947. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang LL, Mu GG, Ding QS, Li YX, Shi YB,
Dai JF and Yu HG: Phosphatase and Tensin Homolog (PTEN) represses
colon cancer progression through inhibiting paxillin transcription
via PI3K/AKT/NF-κB Pathway. J Biol Chem. 290:15018–15029. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qingjuan L, Xiaojuan F, Wei Z, Chao W,
Pengpeng K, Hongbo L, Sanbing Z, Jun H, Min Y and Shuxia L:
miR-148a-3p overexpression contributes to glomerular cell
proliferation by targeting PTEN in lupus nephritis. Am J Physiol
Cell Physiol. 310:C470–C478. 2016. View Article : Google Scholar : PubMed/NCBI
|
